MX2017014725A - Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas. - Google Patents

Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Info

Publication number
MX2017014725A
MX2017014725A MX2017014725A MX2017014725A MX2017014725A MX 2017014725 A MX2017014725 A MX 2017014725A MX 2017014725 A MX2017014725 A MX 2017014725A MX 2017014725 A MX2017014725 A MX 2017014725A MX 2017014725 A MX2017014725 A MX 2017014725A
Authority
MX
Mexico
Prior art keywords
dropropizine
ambroxol
combination
syrup
tablets
Prior art date
Application number
MX2017014725A
Other languages
English (en)
Inventor
Luis Espino Vázquez Jorge
Original Assignee
Productos Farm S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Farm S A De C V filed Critical Productos Farm S A De C V
Priority to MX2017014725A priority Critical patent/MX2017014725A/es
Priority to US16/497,269 priority patent/US20210128496A1/en
Priority to PCT/IB2018/052699 priority patent/WO2019097309A1/es
Priority to PE2019002014A priority patent/PE20191820A1/es
Priority to CR20190401A priority patent/CR20190401A/es
Publication of MX2017014725A publication Critical patent/MX2017014725A/es
Priority to NI201900084A priority patent/NI201900084A/es
Priority to CL2019002446A priority patent/CL2019002446A1/es
Priority to DO2019000233A priority patent/DOP2019000233A/es
Priority to CONC2019/0013645A priority patent/CO2019013645A2/es
Priority to US18/512,349 priority patent/US20240082176A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

La presente invención se refiere a una combinación farmacéutica de ambroxol o una sal farmacéuticamente aceptable del mismo y dropropizina. Asimismo, se refiere a una composición farmacéutica, preferentemente en una forma de administración oral, que contiene dichos ingredientes activos, junto con uno o más aditivos farmacéuticamente aceptables. La invención también se refiere a los procesos de preparación y los procesos de uso de la combinación farmacéutica o la composición farmacéutica de la presente invención.
MX2017014725A 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas. MX2017014725A (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
US16/497,269 US20210128496A1 (en) 2017-11-16 2018-04-19 Dropropizine in combination with ambroxol in the dosage form of syrup or tablets
PCT/IB2018/052699 WO2019097309A1 (es) 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
PE2019002014A PE20191820A1 (es) 2017-11-16 2018-04-19 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas
CR20190401A CR20190401A (es) 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
NI201900084A NI201900084A (es) 2017-11-16 2019-07-31 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CL2019002446A CL2019002446A1 (es) 2017-11-16 2019-08-26 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas.
DO2019000233A DOP2019000233A (es) 2017-11-16 2019-09-12 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta
CONC2019/0013645A CO2019013645A2 (es) 2017-11-16 2019-12-03 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
US18/512,349 US20240082176A1 (en) 2017-11-16 2023-11-17 Dropropizine in combination with ambroxol in the dosage form of syrup and tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Publications (1)

Publication Number Publication Date
MX2017014725A true MX2017014725A (es) 2019-05-17

Family

ID=66538528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Country Status (9)

Country Link
US (2) US20210128496A1 (es)
CL (1) CL2019002446A1 (es)
CO (1) CO2019013645A2 (es)
CR (1) CR20190401A (es)
DO (1) DOP2019000233A (es)
MX (1) MX2017014725A (es)
NI (1) NI201900084A (es)
PE (1) PE20191820A1 (es)
WO (1) WO2019097309A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203721B (it) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
KR101915056B1 (ko) * 2012-04-10 2018-11-07 한미약품 주식회사 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법

Also Published As

Publication number Publication date
CO2019013645A2 (es) 2020-01-17
US20240082176A1 (en) 2024-03-14
CL2019002446A1 (es) 2019-12-13
CR20190401A (es) 2019-11-18
PE20191820A1 (es) 2019-12-27
WO2019097309A1 (es) 2019-05-23
DOP2019000233A (es) 2019-12-15
US20210128496A1 (en) 2021-05-06
NI201900084A (es) 2020-04-02

Similar Documents

Publication Publication Date Title
AU2024202449A1 (en) Compounds for modulating S1P1 activity and methods of using the same
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2017012878A (es) Composiciones gomosas de multicomponentes con nucleo duro.
MY187047A (en) Selective pyy compounds and uses thereof
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201792591A1 (ru) Фармацевтические препараты
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX2017014725A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
PH12020551547A1 (en) Pharmaceutical preparation
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2020006886A (es) Sistema para suministro de medicamento.
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
PH12016502527A1 (en) Stabilized desmopressin
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид